Traders sold shares of Biogen Inc. (NASDAQ:BIIB) on strength during trading on Monday. $174.00 million flowed into the stock on the tick-up and $199.59 million flowed out of the stock on the tick-down, for a money net flow of $25.59 million out of the stock. Of all equities tracked, Biogen had the 21st highest net out-flow for the day. Biogen traded up $7.56 for the day and closed at $313.59

Several brokerages have recently weighed in on BIIB. Jefferies Group reiterated a “buy” rating and issued a $319.00 price target on shares of Biogen in a research report on Thursday, August 4th. Robert W. Baird restated a “neutral” rating and set a $284.00 target price on shares of Biogen in a research report on Wednesday, August 10th. Standpoint Research cut Biogen from a “buy” rating to a “hold” rating in a research report on Tuesday, August 2nd. Leerink Swann restated a “market perform” rating and set a $319.00 target price on shares of Biogen in a research report on Wednesday, June 1st. Finally, Piper Jaffray Cos. restated a “hold” rating and set a $293.00 target price on shares of Biogen in a research report on Tuesday, June 7th. Ten research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $345.89.

The company has a market cap of $68.71 billion and a P/E ratio of 18.32. The firm has a 50 day moving average of $302.07 and a 200-day moving average of $271.44.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Thursday, July 21st. The biotechnology company reported $5.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.69 by $0.52. The firm earned $2.89 billion during the quarter, compared to analysts’ expectations of $2.79 billion. During the same period in the prior year, the firm posted $4.22 earnings per share. Biogen’s revenue for the quarter was up 11.7% compared to the same quarter last year. Analysts forecast that Biogen Inc. will post $20.11 earnings per share for the current fiscal year.

In other Biogen news, CEO George A. Scangos sold 157 shares of Biogen stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $280.00, for a total value of $43,960.00. Following the transaction, the chief executive officer now directly owns 54,779 shares of the company’s stock, valued at $15,338,120. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.